Strand Therapeutics
The pipeline identifies STX-005 as a circular mRNA circuit for in vivo CAR-T in autoimmune disease and blood cancers. Clinical findings from the separate IL-12 programs STX-001/003 must not be attributed to STX-005; current CAR-T clinical initiation was not verified.
Corporate information
- Company entity
- Strand Therapeutics
- Headquarters / principal office
- Boston, MassachusettsSelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters. ↗
- Founded
- 2017 ↗
- Ownership / capital status
- PrivateSeries B ↗
- Official corporate reference
- https://www.strandtx.com/pipeline ↗
- LinkedIn company page
- LinkedIn ↗ ↗
- Latest financing / award identified
- 2025-08-07 · Series B · US$153 million ↗
Disclosed equity event found in this review; not a claim that no later undisclosed event exists.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
The pipeline identifies STX-005 as a circular mRNA circuit for in vivo CAR-T in autoimmune disease and blood cancers. Clinical findings from the separate IL-12 programs STX-001/003 must not be attributed to STX-005; current CAR-T clinical initiation was not verified.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Pipeline | First-in-Class mRNA Therapies - Strand Signal — official page checked
- Company financing announcement
- Company-managed LinkedIn profile — self-reported location